CN102317280B - 具有胃动素受体激动活性的羟基吲哚衍生物 - Google Patents
具有胃动素受体激动活性的羟基吲哚衍生物 Download PDFInfo
- Publication number
- CN102317280B CN102317280B CN201080007432.5A CN201080007432A CN102317280B CN 102317280 B CN102317280 B CN 102317280B CN 201080007432 A CN201080007432 A CN 201080007432A CN 102317280 B CN102317280 B CN 102317280B
- Authority
- CN
- China
- Prior art keywords
- dimethyl
- piperidin
- oxo
- oxoindolan
- methylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)(CN*)C(*)(*)C(C)(C)C(N(CC1)CCC1N(C(*1**)=O)c2c1cccc2)=O Chemical compound CC(C)(CN*)C(*)(*)C(C)(C)C(N(CC1)CCC1N(C(*1**)=O)c2c1cccc2)=O 0.000 description 8
- MSKHCMRUDDYZGG-AZKKKJBWSA-N CC(C)(c1ccccc1N1C(CC2)CCN2C([C@H](CCc2ccccc2)N(C)C(NC2CNCCC2)=O)=O)C1=O Chemical compound CC(C)(c1ccccc1N1C(CC2)CCN2C([C@H](CCc2ccccc2)N(C)C(NC2CNCCC2)=O)=O)C1=O MSKHCMRUDDYZGG-AZKKKJBWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20243009P | 2009-02-27 | 2009-02-27 | |
| US61/202,430 | 2009-02-27 | ||
| US28217309P | 2009-12-24 | 2009-12-24 | |
| US61/282,173 | 2009-12-24 | ||
| PCT/JP2010/001368 WO2010098145A1 (en) | 2009-02-27 | 2010-03-01 | Oxyindole derivatives with motilin receptor agonistic activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102317280A CN102317280A (zh) | 2012-01-11 |
| CN102317280B true CN102317280B (zh) | 2014-07-23 |
Family
ID=42665356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080007432.5A Active CN102317280B (zh) | 2009-02-27 | 2010-03-01 | 具有胃动素受体激动活性的羟基吲哚衍生物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8697877B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2401268B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5663743B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101575703B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102317280B (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1007962A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2750699C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2547415T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011008857A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2533116C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010098145A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014106238A1 (en) | 2012-12-31 | 2014-07-03 | Fang, Qun, Kevin | Heterocyclic compounds and methods of use thereof |
| EP3063141B1 (en) * | 2013-10-29 | 2018-02-28 | BioMarin Pharmaceutical Inc. | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors |
| CN106659697B (zh) * | 2014-05-30 | 2022-03-29 | 斯菲叶尔制药私有公司 | 作为抗结核剂的化合物 |
| CA3223173A1 (en) * | 2021-07-30 | 2023-02-02 | Raqualia Pharma Inc. | Crystalline forms |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5767118A (en) * | 1994-10-26 | 1998-06-16 | Merck & Co., Inc. | 4-Heterocyclic peperidines promote release of growth hormone |
| WO2008000729A1 (en) * | 2006-06-28 | 2008-01-03 | Glaxo Group Limited | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases |
| CN101272782A (zh) * | 2005-08-15 | 2008-09-24 | 阿特纳赞塔里斯有限公司 | 作为生长激素促分泌受体的ghrelin类似物配体的新颖的三唑衍生物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW355711B (en) | 1992-11-04 | 1999-04-11 | Chugai Pharmaceutical Co Ltd | Erythromycin derivatives |
| JP3449766B2 (ja) | 1993-11-19 | 2003-09-22 | 中外製薬株式会社 | モチリンアンタゴニスト |
| JP3901239B2 (ja) | 1996-03-13 | 2007-04-04 | 大正製薬株式会社 | アリールアルカン誘導体 |
| US5734012A (en) | 1996-05-16 | 1998-03-31 | Ohmeda Pharmaceutical Products Division Inc. | Cyclic motilin-like polypeptides with gastrointestinal motor stimulating activity |
| DE19644195A1 (de) | 1996-10-24 | 1998-04-30 | Solvay Pharm Gmbh | 10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6100239A (en) | 1996-11-26 | 2000-08-08 | Chugai Seiyaku Kabushiki Kaisha | 13-membered ring macrolide compound, medicine containing the same, and process for producing the same |
| TWI242011B (en) * | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US5972939A (en) | 1997-10-28 | 1999-10-26 | Ortho-Mcneil Pharmaceutical, Inc. | Cyclopentene derivatives useful as antagonists of the motilin receptor |
| DE19805822B4 (de) | 1998-02-13 | 2009-02-05 | Solvay Pharmaceuticals Gmbh | 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6165985A (en) | 1998-02-13 | 2000-12-26 | Solvay Pharmaceuticals Gmbh | 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them |
| WO2001068622A1 (en) | 2000-03-13 | 2001-09-20 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclobutene derivatives useful as antagonists of the motilin receptor |
| WO2001068621A1 (en) | 2000-03-13 | 2001-09-20 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclohexene derivatives useful as antagonists of the motilin receptor |
| WO2001068620A1 (en) | 2000-03-13 | 2001-09-20 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclopentene derivatives useful as antagonists of the motilin receptor |
| US6511980B2 (en) | 2000-05-05 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Substituted diamine derivatives useful as motilin antagonists |
| JP2004529184A (ja) * | 2001-05-10 | 2004-09-24 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規１−アミドメチルカルボニル−ピペリジン誘導体、該誘導体を製造するための方法及び中間体並びにこれらの化合物を含有している医薬 |
| JP4928263B2 (ja) | 2003-07-31 | 2012-05-09 | トランザイム・ファーマ | ペプチド結合サロゲートを組み入れた空間的に規定された大環状分子 |
| DE602004030344D1 (de) | 2003-07-31 | 2011-01-13 | Tranzyme Pharma Inc | Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen |
| US7262195B2 (en) | 2003-09-17 | 2007-08-28 | Bristol-Myers Squibb Company | Compounds useful as motilin agonists and method |
| US7338954B2 (en) | 2003-09-17 | 2008-03-04 | Bristol-Myers Squibb Company | Compounds useful as motilin agonists and method |
| WO2006011035A1 (en) | 2004-07-23 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them |
| AU2006217534B8 (en) * | 2005-02-22 | 2011-12-08 | Pfizer Inc. | Oxyindole derivatives as 5HT4 receptor agonists |
| US7582611B2 (en) | 2005-05-24 | 2009-09-01 | Pfizer Inc. | Motilide compounds |
| WO2007007018A1 (en) | 2005-07-12 | 2007-01-18 | Glaxo Group Limited | Piperazine heteroaryl derivates as gpr38 agonists |
| JO2747B1 (en) | 2005-07-26 | 2014-03-15 | جلاكسو جروب ليمتد | Vehicles |
-
2010
- 2010-03-01 JP JP2011536661A patent/JP5663743B2/ja active Active
- 2010-03-01 WO PCT/JP2010/001368 patent/WO2010098145A1/en not_active Ceased
- 2010-03-01 MX MX2011008857A patent/MX2011008857A/es active IP Right Grant
- 2010-03-01 RU RU2011139287/04A patent/RU2533116C2/ru active IP Right Revival
- 2010-03-01 US US13/203,301 patent/US8697877B2/en active Active
- 2010-03-01 CN CN201080007432.5A patent/CN102317280B/zh active Active
- 2010-03-01 ES ES10746028.9T patent/ES2547415T3/es active Active
- 2010-03-01 KR KR1020117021833A patent/KR101575703B1/ko active Active
- 2010-03-01 BR BRPI1007962A patent/BRPI1007962A2/pt not_active IP Right Cessation
- 2010-03-01 EP EP10746028.9A patent/EP2401268B1/en active Active
- 2010-03-01 CA CA2750699A patent/CA2750699C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5767118A (en) * | 1994-10-26 | 1998-06-16 | Merck & Co., Inc. | 4-Heterocyclic peperidines promote release of growth hormone |
| CN101272782A (zh) * | 2005-08-15 | 2008-09-24 | 阿特纳赞塔里斯有限公司 | 作为生长激素促分泌受体的ghrelin类似物配体的新颖的三唑衍生物 |
| WO2008000729A1 (en) * | 2006-06-28 | 2008-01-03 | Glaxo Group Limited | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1164318A1 (en) | 2012-09-21 |
| WO2010098145A1 (en) | 2010-09-02 |
| US8697877B2 (en) | 2014-04-15 |
| EP2401268A4 (en) | 2013-01-02 |
| RU2011139287A (ru) | 2013-04-10 |
| US20110312933A1 (en) | 2011-12-22 |
| RU2533116C2 (ru) | 2014-11-20 |
| ES2547415T3 (es) | 2015-10-06 |
| CA2750699A1 (en) | 2010-09-02 |
| BRPI1007962A2 (pt) | 2016-02-23 |
| MX2011008857A (es) | 2011-09-30 |
| KR20110133033A (ko) | 2011-12-09 |
| JP2012519153A (ja) | 2012-08-23 |
| EP2401268B1 (en) | 2015-07-29 |
| EP2401268A1 (en) | 2012-01-04 |
| CN102317280A (zh) | 2012-01-11 |
| CA2750699C (en) | 2015-12-29 |
| JP5663743B2 (ja) | 2015-02-04 |
| KR101575703B1 (ko) | 2015-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3037650T3 (en) | Heterocyclic compounds and use thereof | |
| CN102164920B (zh) | 烷基噻唑氨基甲酸酯衍生物、其制备方法和其作为faah酶抑制剂的用途 | |
| TW202134229A (zh) | 環烷基尿素衍生物 | |
| JP5306821B2 (ja) | レニン阻害剤としての３，５−置換ピペリジン化合物 | |
| TW201734001A (zh) | ＲＯＲ－γ調節劑 | |
| TW201043619A (en) | 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof and therapeutic use thereof | |
| TW201625538A (zh) | 新穎吡啶衍生物 | |
| CN113754654A (zh) | 咪唑并吡啶类化合物及其用途 | |
| CN108026050A (zh) | 作为RORγ调节剂的新型化合物 | |
| MX2007001514A (es) | Compuestos quimicos. | |
| CN108349901A (zh) | 作为大麻素受体2激动剂的苯基衍生物 | |
| CN102112451B (zh) | 用作趋化因子受体调节剂的二氮杂环庚烷和哌嗪衍生物 | |
| CN102317280A (zh) | 具有胃动素受体激动活性的羟基吲哚衍生物 | |
| CN110753690A (zh) | 吡啶衍生物 | |
| KR101586507B1 (ko) | 아미드 유도체 및 이를 함유하는 약학적 조성물 | |
| AU2006236622B2 (en) | Compositions of novel opioid compounds and method of use thereof | |
| JP2012519153A5 (cg-RX-API-DMAC7.html) | ||
| JP5771531B2 (ja) | ヒスタミンｈ３受容体アンタゴニストとしてのアゼチジン | |
| WO2017008681A1 (zh) | 酰胺类衍生物、其制备方法及其在医药上的用途 | |
| HK1164318B (en) | Oxyindole derivatives with motilin receptor agonistic activity | |
| WO2022022364A1 (zh) | 一种吡咯烷类整合素调节剂及其用途 | |
| CN121712748A (zh) | 作为sstr4激动剂的(2s,5r)-5-(羟甲基)吗啉-2-甲酰胺 | |
| CA2573446A1 (fr) | Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique | |
| HK40019933A (en) | Pyridine derivatives | |
| HK40019933B (zh) | 吡啶衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |